NCT07754461
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 101 → 121 locations
- Minor Trial sites reduced: 121 → 101 locations
- Minor Study sites: 121 to 120
- Minor Site details revised at 26 of 121 sites
- Notable Eligibility criteria expanded, about 18 words
- Secondary endpoints: details revised at 3 of 11 entries
- Study sites revised (121)
- Minor Study sites: 120 to 121v3
- Notable Recruitment opened
- Trial sites expanded: 115 → 120 locations
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Placebo as an add-on to diet and exercise.
Low-dose survodutide as an add-on to diet and exercise.
High-dose survodutide as add-on to diet and exercise
Placebo as an add-on to anti-diabetic drugs.
Low-dose survodutide as an add-on to anti-diabetic drugs.
High-dose survodutide as an add-on to anti-diabetic drugs.
Placebo as an add-on to basal insulin therapy with or without anti-diabetic drugs.
Low-dose as an add-on to basal insulin therapy with or without anti-diabetic drugs.
High-dose as an add-on to basal insulin therapy with or without anti-diabetic drugs.
Drugs: Placebo, Survodutide
Sites
121 sites in 6 countries
United States 90, India 13, Canada 10, Australia 4, New Zealand 3, Puerto Rico 1